Loteprednol
- Atc Codes:S01BA14
- CAS Codes:82034-46-6#129260-79-3
- PHARMGKB ID:82034-46-6#129260-79-3
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Lotemax; Cyprus: Lotemax; Estonia: Lotemax; Germany: Lotemax; Ireland: Lotemax; Latvia: Lotemax; Lithuania: Lotemax; Poland: Lotebon, Lotemax; Slovakia: Lotemax; Slovenia: Lotemax; UK: Lotemax.
North America
Canada: Alrex, Lotemax; USA: Alrex, Lotemax.
Latin America
Argentina: Alrex, Lopred, Lotemax, Lotesoft, Talof; Mexico: Loterex, Lotesoft.
Drug combinations
Loteprednol and Tobramycin
Chemistry
Loteprednol Etabonate: C~24~H~31~ClO~7~. Mw: 466.95. (1) Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11β,17α)-; (2) Chloromethyl 11β,17-dihydroxy-3-oxoandrosta-1,4-diene-17β-carboxylate, 17-(ethyl carbonate). CAS-82034-46-6; CAS-129260-79-3 (loteprednol)(1990).
Pharmacologic Category
EENT Preparations; Anti-inflammatory Agents; Corticosteroids. Ophthalmic Corticosteroid. (ATC-Code: S01BA14).
Mechanism of action
Loteprednol is highly lipid-soluble and penetrates cells readily to induce production of lipocortins. These proteins modulate activity of prostaglandins and leukotrienes.
Therapeutic use
Temporary relief of signs and symptoms of seasonal allergic conjunctivitis. Treatment of steroid-responsive inflammatory conditions of postoperative inflammation following ocular surgery.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to loteprednol, other corticosteroids, and any component of the formulation. Viral diseases of cornea and conjunctiva. Mycobacterial eye infection. Fungal diseases of ocular structures.
Warnings and precautions
Steroids may mask infection or enhance existing ocular infection. Prolonged use may result in secondary infections due to immunosuppression. Prolonged use may result in glaucoma and injury to optic nerve. Visual defects in acuity and field of vision may occur. Posterior subcapsular cataracts may form after long-term use. Use with caution in presence of glaucoma (steroids increase intraocular pressure). Perforation may occur with topical steroids in diseases which thin cornea or sclera. Steroid use may delay healing after cataract surgery. For ophthalmic use only.